Skip to content
PubMed This is a summary of 47 peer-reviewed journal articles Updated
Immunology

Mendelian Susceptibility to Mycobacterial Diseases due to Partial IRF8 Deficiency: A Patient Guide

At a Glance

Partial IRF8 deficiency is a rare inherited immune condition that can make people vulnerable to environmental mycobacteria and infection after BCG vaccination. Severity varies widely, so personalized prevention and lifelong follow-up with immunology and infectious disease specialists are important.

Note: This guide is intended for patients of all ages, as well as parents and caregivers. Because “partial IRF8 deficiency” is a molecularly and clinically heterogeneous diagnosis, presentation and management vary widely. This guide cannot replace your individualized medical, fever, or treatment plans.

Mendelian Susceptibility to Mycobacterial Diseases (MSMD) due to partial IRF8 deficiency is a rare genetic condition that alters how your immune system identifies and responds to specific types of germs. Your immune system is made up of many specialized “soldier” cells, and the IRF8 gene acts as a master architect that tells these cells how to grow and what jobs to perform [1]. When there is a partial deficiency in this gene, the architecture of the immune system is slightly shifted: the body may struggle to produce enough of certain “sentinel” cells, called dendritic cells, while potentially making more of others to compensate [1][2].

Because of this subtle cellular imbalance, the immune system develops a specific “blind spot” for mycobacteria—a family of slow-growing bacteria that includes the tuberculosis germ as well as common, usually harmless bacteria found in soil and water [3]. This means that a person with partial IRF8 deficiency may become ill from environmental exposures or vaccines (like the BCG vaccine) that most people’s immune systems would handle without any trouble [4]. While the condition also creates a potential vulnerability to certain viruses depending on the specific variant, it is important to know that the severity of these symptoms is highly variable [5]. Some individuals may experience significant infections early in life, while others may have very few symptoms and only discover the condition through genetic testing of family members [2].

One of the most reassuring aspects of a “partial” diagnosis is that it is distinct from the “complete” form of the deficiency, which is much more severe and typically appears in early infancy [6]. In the partial form, the immune system still possesses many of its essential tools, it simply needs extra support to use them effectively. However, partial disease can still cause severe disseminated infection, and outcome depends heavily on the exact variant and infection history. Living with this condition involves a shift toward proactive, lifelong health management [7]. By working with a multidisciplinary care team—including specialists in immunology and infectious disease—you can create a tailored plan that focuses on preventing infections and monitoring the immune system’s health over time [7].

Ultimately, an IRF8 diagnosis marks the end of a search for answers and the beginning of an empowered approach to health. With modern genetic testing and specialized care, patients and families can move forward with a clear understanding of why these infections happen and a concrete plan to manage them. This guide is designed to help you navigate that journey, providing the knowledge you need to advocate for the best possible care [8].

Common questions in this guide

What is partial IRF8 deficiency, and how is it related to MSMD?
Partial IRF8 deficiency is a rare inherited condition in which the IRF8 gene does not work fully. IRF8 helps immune cells develop and coordinate their responses, so the deficiency can create a specific vulnerability to mycobacteria, including environmental bacteria and the BCG vaccine strain. It is one genetic cause of Mendelian susceptibility to mycobacterial diseases, or MSMD.
Is partial IRF8 deficiency milder than complete IRF8 deficiency?
Partial deficiency usually leaves more immune function than complete deficiency, which is typically more severe and appears in early infancy. However, partial deficiency can still cause severe disseminated infection. The long-term outlook depends greatly on the exact IRF8 variant and the person’s infection history.
What infections can occur with partial IRF8 deficiency?
People may become ill from environmental mycobacteria found in soil and water or from bacteria that cause tuberculosis. The BCG vaccine can also be a concern, and some variants may increase vulnerability to certain viruses. The type and severity of infection vary widely from person to person.
How is partial IRF8 deficiency diagnosed?
Genetic testing can identify a change affecting the IRF8 gene, and testing family members may find people who have few symptoms. Clinicians interpret the genetic result together with the person’s infection history and clinical findings. This helps the care team understand the diagnosis and plan monitoring.
What should I know about vaccines with partial IRF8 deficiency?
Do not change a vaccine schedule without discussing it with the care team. Inactivated vaccines and live vaccines require separate review, and BCG may pose a risk for someone with susceptibility to mycobacterial disease. Immunology and infectious disease specialists can consider the person’s variant, infection history, and vaccine risks when making recommendations.
How is partial IRF8 deficiency managed over time?
Management is individualized because partial IRF8 deficiency can vary substantially between people. A multidisciplinary team can create infection-prevention and fever plans, review vaccines and environmental exposures, and monitor immune health over time. Ongoing follow-up with immunology and infectious disease specialists supports proactive, long-term care.
Which warning signs should prompt urgent contact with the medical team?
There is no single warning-sign list that fits every person because age, genetic variant, and infection history affect risk. Ask your medical team for a written plan explaining when to call about fever, suspected infection, or possible mycobacterial exposure. Follow that individualized plan rather than relying on general advice.

Get notified when new evidence is published on Mendelian susceptibility to mycobacterial diseases due to partial IRF8 deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (8)
  1. 1

    Differential IRF8 Transcription Factor Requirement Defines Two Pathways of Dendritic Cell Development in Humans.

    Cytlak U, Resteu A, Pagan S, et al.

    Immunity 2020; (53(2)):353-370.e8 doi:10.1016/j.immuni.2020.07.003.

    PMID: 32735845
  2. 2

    A novel dominant-negative variant of IRF8 in a mother and son: Clinical, phenotypic and biological characteristics.

    Ham H, Isham CR, Ristagno EH, et al.

    The Journal of allergy and clinical immunology 2025; (155(6)):2022-2037 doi:10.1016/j.jaci.2024.11.041.

    PMID: 40072380
  3. 3

    Mendelian susceptibility to mycobacterial disease: IFN-γ-driven immunity collapse underlies heterogeneous infections.

    Qian M, Zhou J, Zhou Q, et al.

    Frontiers in immunology 2026; (17()):1781297 doi:10.3389/fimmu.2026.1781297.

    PMID: 42183200
  4. 4

    Inborn errors of human transcription factors governing IFN-γ antimycobacterial immunity.

    Ogishi M, Yang R, Rosain J, et al.

    Current opinion in immunology 2023; (81()):102296 doi:10.1016/j.coi.2023.102296.

    PMID: 36867972
  5. 5

    Case Report: A patient with a novel heterozygous IRF8 variant with repeated infection and immune-mediated organ disease, but without disseminated mycobacterial disease despite BCG immunization.

    Chiang SCC, Owsley E, Husami A, et al.

    Frontiers in immunology 2025; (16()):1654617 doi:10.3389/fimmu.2025.1654617.

    PMID: 41229418
  6. 6

    Pulmonary Alveolar Proteinosis and Multiple Infectious Diseases in a Child with Autosomal Recessive Complete IRF8 Deficiency.

    Rosain J, Bernasconi A, Prieto E, et al.

    Journal of clinical immunology 2022; (42(5)):975-985 doi:10.1007/s10875-022-01250-4.

    PMID: 35338423
  7. 7

    Clinical recommendations for diagnosis and management of Mendelian susceptibility to mycobacterial disease in resource-limited settings.

    Cornelissen H, Glanzmann B, van Coller A, et al.

    The journal of allergy and clinical immunology. Global 2025; (4(4)):100540 doi:10.1016/j.jacig.2025.100540.

    PMID: 41048447
  8. 8

    "It's a Godsend": Parental experiences of genomic testing for paediatric inborn errors of immunity.

    Clark A, DeBortoli E, Blancoe M, et al.

    European journal of human genetics : EJHG 2025; (33(10)):1342-1349 doi:10.1038/s41431-025-01917-7.

    PMID: 40730688

This page is for informational purposes only and does not constitute medical advice. It cannot replace an individualized fever, vaccination, or treatment plan from an immunology or infectious disease specialist.